Johnson & Johnson stock: EUR 247.98, up 2.26% premarket
Published on 11/05/2026 at 07:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points for investors
- Johnson & Johnson focuses on healthcare innovation spanning disease prevention, treatment and cures.
- The company reports more than 60 consecutive years of dividend increases.
- Johnson & Johnson says more than 75% of sales come from products holding a number-one or number-two global market position.
Johnson & Johnson stock is moving higher before the European session after the latest US healthcare trading. The company focuses on healthcare innovation spanning disease prevention, treatment and cures, according to Johnson & Johnson Investor Relations.
Johnson & Johnson stock traded at EUR 247.98 on Lang & Schwarz at 07:57 CET on Thursday, November 5, 2026, 2.26% above the Xetra close of Wednesday, November 4, 2026 at EUR 242.50; see the real-time quote of Johnson & Johnson stock.
Healthcare scale supports investor focus
Investor Relations highlights more than 60 consecutive years of dividend increases and says that more than 75% of sales come from products with a number-one or number-two global market share position. Those indicators point to scale and shareholder-return continuity, while the premarket move places the stock above the latest Xetra reference.
US equity sentiment will remain part of the backdrop through the S&P 500.
